Results 161 to 170 of about 28,175 (193)
Some of the next articles are maybe not open access.
Romiplostim in a Case Series of Chemotherapy-Induced Thrombocytopenia
Blood, 2011Abstract 1170 Thrombocytopenia is a common effect of cytotoxic chemotherapy regimens in cancer patients, often necessitating reduction or delay in subsequent cycles. While the thrombocytopenia typically resolves with time, a subset of patients (pts) with chemotherapy-induced thrombocytopenia (CIT) have prolonged thrombocytopenia, of ...
Rekha Parameswaran, Gerald A. Soff
openaire +1 more source
Impact of Romiplostim on Overall Survival in Chemotherapy Induced Thrombocytopenia
Blood, 2023BACKGROUND Romiplostim, a thrombopoietin receptor agonist, has been shown in a phase 2 trial to increase platelet count and facilitate chemotherapy administration in the setting of chemotherapy induced thrombocytopenia (CIT).
Cy R Wilkins +3 more
openaire +1 more source
A second chance for avatrombopag in chemotherapy‐induced thrombocytopenia
British Journal of HaematologyChemotherapy‐induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end‐point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT ...
Hanny Al‐Samkari, Donald C. Moore
openaire +2 more sources
The Protective Effect of Sweet Potato Root Tuber on Chemotherapy‐Induced Thrombocytopenia
Molecular Nutrition & Food Research, 2022ScopeSweet potato (Ipomoea batatas L.) is one of the leading crops worldwide, containing high nutritional components such as fiber and polyphenols. Root tuber of Simon 1 (SIMON), a cultivar of sweet potato, is a folk food in China with a hemostasis function but lacking experimental data support.Methods and resultsNow the protective effect of SIMON on ...
Zi‐Heng Qi +11 more
openaire +2 more sources
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia
Current Opinion in Oncology, 2008This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia.A new generation of thrombopoietic agents have had preliminary success in the treatment of thrombocytopenia. The initial thrombopoietic agents were recombinant and pegylated human megakaryocyte growth
Benjamin, Levy +2 more
openaire +2 more sources
Life Sciences, 2020
Platelet production improvement can resolve concerns about the limitations of external platelet supply and platelet transfusion in thrombocytopenia patients. To this end, scientists encourage to induce the generation of megakaryocyte and platelet. Curcumin is a safe ingredient of turmeric that affects various cellular pathways.
Seyedeh Sahar, Mortazavi Farsani +4 more
openaire +2 more sources
Platelet production improvement can resolve concerns about the limitations of external platelet supply and platelet transfusion in thrombocytopenia patients. To this end, scientists encourage to induce the generation of megakaryocyte and platelet. Curcumin is a safe ingredient of turmeric that affects various cellular pathways.
Seyedeh Sahar, Mortazavi Farsani +4 more
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes.
Jill S, Bates +2 more
openaire +2 more sources
Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes.
Jill S, Bates +2 more
openaire +2 more sources
Management of Chemotherapy-Induced Thrombocytopenia: Current Status of Thrombopoietic Agents
Seminars in Hematology, 2009Myelosuppression, one of the most common toxicities of chemotherapy, results in varying degree of cytopenias. While neutropenia and anemia have been reduced with the currently approved hematopoietic growth factors, thrombocytopenia remains a significant clinical problem with an unmet medical need.
openaire +2 more sources
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia
The Lancet Haematology, 2022Maria L, Lozano, Francesco, Rodeghiero
openaire +2 more sources
Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
Seminars in Hematology, 2000Since the identification and cloning of c-Mpl ligand, two forms of recombinant human thrombopoietin have undergone clinical development. Both the full-length molecule, known as rhTPO, and the truncated version of the molecule, known as pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), have been evaluated in phase I ...
openaire +2 more sources